UK markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.000.00 (0.00%)
At close: 12:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.12B
Enterprise value 1.05B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)28.17
Price/book (mrq)52.69
Enterprise value/revenue 41.45
Enterprise value/EBITDA -21.13

Trading information

Stock price history

Beta (5Y monthly) 1.40
52-week change 3220.00%
S&P500 52-week change 320.07%
52-week high 310.90
52-week low 30.60
50-day moving average 36.42
200-day moving average 32.32

Share statistics

Avg vol (3-month) 3431
Avg vol (10-day) 3290
Shares outstanding 5139.85M
Implied shares outstanding 6139.51M
Float 872.94M
% held by insiders 129.54%
% held by institutions 133.85%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -170.51%
Operating margin (ttm)-633.59%

Management effectiveness

Return on assets (ttm)-30.80%
Return on equity (ttm)-221.19%

Income statement

Revenue (ttm)25.38M
Revenue per share (ttm)0.68
Quarterly revenue growth (yoy)-56.00%
Gross profit (ttm)N/A
EBITDA -49.27M
Net income avi to common (ttm)-43.27M
Diluted EPS (ttm)-0.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)54.03M
Total cash per share (mrq)0.39
Total debt (mrq)272k
Total debt/equity (mrq)1.59%
Current ratio (mrq)4.56
Book value per share (mrq)0.43

Cash flow statement

Operating cash flow (ttm)-39.35M
Levered free cash flow (ttm)-22.88M